Interleukin 21: combination strategies for cancer therapy (Q37079691)

18 August 2017

1 reference

title

Interleukin 21: combination strategies for cancer therapy (English)

1 reference

Erratum: Interleukin 21: combination strategies for cancer therapy

18 August 2017

0 references

corrigendum / erratum

0 references

Mark J Smyth

4

0 references

author name string

Kresten Skak

1

1 reference

18 August 2017

Michael Kragh

2

1 reference

18 August 2017

Diana Hausman

3

1 reference

18 August 2017

Pallavur V Sivakumar

5

1 reference

18 August 2017

1 March 2008

1 reference

Nature Reviews Drug Discovery

18 August 2017

1 reference

18 August 2017

7

1 reference

18 August 2017

3

1 reference

18 August 2017

231-240

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2482

18 August 2017

0 references

cites work

CD8+ T-cell memory in tumor immunology and immunotherapy

1 reference

Historical markers in the development of allogeneic hematopoietic cell transplantation

31 March 2020

1 reference

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents

31 March 2020

1 reference

Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment

31 March 2020

1 reference

Therapeutic vaccines for melanoma: current status

31 March 2020

1 reference

Adoptive-cell-transfer therapy for the treatment of patients with cancer

31 March 2020

1 reference

Treatment of metastatic malignant melanoma

31 March 2020

1 reference

Immunotherapy for renal cell cancer

31 March 2020

1 reference

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

31 March 2020

1 reference

Monoclonal antibody therapy for B-cell malignancies

31 March 2020

1 reference

HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy

31 March 2020

1 reference

Recent developments in colorectal cancer treatment by monoclonal antibodies

31 March 2020

1 reference

Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia

31 March 2020

1 reference

Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer

31 March 2020

1 reference

Cancer vaccines as a therapeutic modality: The long trek

31 March 2020

1 reference

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma

31 March 2020

1 reference

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

31 March 2020

1 reference

IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production

31 March 2020

1 reference

T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells

31 March 2020

1 reference

IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade

31 March 2020

1 reference

IL-21 induces the functional maturation of murine NK cells

31 March 2020

1 reference

Cytokine requirements for the growth and development of mouse NK cells in vitro.

31 March 2020

1 reference

Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

31 March 2020

1 reference

A critical role for IL-21 in regulating immunoglobulin production

31 March 2020

1 reference

Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration

31 March 2020

1 reference

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

31 March 2020

1 reference

IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells

31 March 2020

1 reference

Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

31 March 2020

1 reference

IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes

31 March 2020

1 reference

IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response

31 March 2020

1 reference

IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells

31 March 2020

1 reference

IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes

31 March 2020

1 reference

Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation

31 March 2020

1 reference

Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma

31 March 2020

1 reference

Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses.

31 March 2020

1 reference

Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

31 March 2020

1 reference

Perforin-mediated target-cell death and immune homeostasis

31 March 2020

1 reference

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma

31 March 2020

1 reference

Interleukin-21 enhances NK cell activation in response to antibody-coated targets

31 March 2020

1 reference

IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors

31 March 2020

1 reference

IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21

31 March 2020

1 reference

Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors

31 March 2020

1 reference

Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts

31 March 2020

1 reference

IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice

31 March 2020

1 reference

Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response

31 March 2020

1 reference

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

31 March 2020

1 reference

IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype

31 March 2020

1 reference

IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells

31 March 2020

1 reference

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

31 March 2020

1 reference

Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

31 March 2020

1 reference

IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells.

31 March 2020

1 reference

Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma.

31 March 2020

1 reference

Quadrivalent human papillomavirus recombinant vaccine

31 March 2020

1 reference

Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery

31 March 2020

1 reference

Targeting the EGFR pathway for cancer therapy

31 March 2020

1 reference

From the bench to the bedside: ways to improve rituximab efficacy.

31 March 2020

1 reference

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

31 March 2020

1 reference

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

31 March 2020

1 reference

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma

31 March 2020

1 reference

Targeting Tumor-Related Immunosuppression for Cancer Immunotherapy

31 March 2020

1 reference

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

31 March 2020

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

31 March 2020

1 reference

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells

31 March 2020

1 reference

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

31 March 2020

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

31 March 2020

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

Regulatory T cells in cancer

31 March 2020

1 reference

Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy

31 March 2020

1 reference

Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma

31 March 2020

1 reference

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine

31 March 2020

1 reference

NKT cells: what's in a name?

31 March 2020

1 reference

NKT cells and tumor immunity—a double-edged sword

31 March 2020

1 reference

Going both ways: immune regulation via CD1d-dependent NKT cells

31 March 2020

1 reference

CD1: antigen presentation and T cell function

31 March 2020

1 reference

Alpha-galactosylceramide: potential immunomodulatory activity and future application

31 March 2020

1 reference

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

31 March 2020

1 reference

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells

31 March 2020

1 reference

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients

31 March 2020

1 reference

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

31 March 2020

1 reference

Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer

31 March 2020

1 reference

Following the TRAIL to apoptosis

31 March 2020

1 reference

The clinical trail of TRAIL.

31 March 2020

1 reference

TRAIL receptor-targeted therapy.

31 March 2020

1 reference

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

31 March 2020

1 reference

Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy

31 March 2020

1 reference

IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy

31 March 2020

1 reference

Immunotherapy and chemotherapy--a practical partnership

31 March 2020

1 reference

Calreticulin exposure dictates the immunogenicity of cancer cell death

31 March 2020

1 reference

Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12.

31 March 2020

1 reference

Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.

31 March 2020

1 reference

A small molecule-kinase interaction map for clinical kinase inhibitors

31 March 2020

1 reference

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

31 March 2020

1 reference

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

31 March 2020

1 reference

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

31 March 2020

1 reference

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

31 March 2020

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

A novel dendritic cell subset involved in tumor immunosurveillance

31 March 2020

1 reference

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

31 March 2020

1 reference

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

31 March 2020

1 reference

Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways

31 March 2020

1 reference

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

31 March 2020

1 reference

Development in motion: helper T cells at work

31 March 2020

1 reference

Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C(epsilon) transcription of IL-4-stimulated B cells

31 March 2020

1 reference

Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells

31 March 2020

1 reference

IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response

31 March 2020

1 reference

Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6

31 March 2020

1 reference

Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21.

31 March 2020

1 reference

Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis

31 March 2020

1 reference

IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

31 March 2020

1 reference

IL-21 induces the apoptosis of resting and activated primary B cells

31 March 2020

1 reference

Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells

31 March 2020

1 reference

Interleukin-21 inhibits dendritic cell activation and maturation

31 March 2020

1 reference

Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo

31 March 2020

1 reference

In vivo and in vitro roles of IL-21 in inflammation.

31 March 2020

1 reference

The IL-21 receptor augments Th2 effector function and alternative macrophage activation

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2482

1 reference

18 August 2017

1 reference